Effectiveness of 190 µg Fluocinolone Acetonide and 700 µg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The CONSTANT Analysis

References

• Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–564. doi:10.2337/dc11-1909
   PubMed Web of Science ®Google Scholar
• American Academy of Ophthalmology (AAO). About Preferred Practice Patterns (PPPs) - American academy of ophthalmology. Available from: https://www.aao.org/about-preferred-practice-patterns. Accessed May 15, 2020.
   Google Scholar
• Boyer DS, Nguyen QD, Brown DM, Basu K, Ehrlich JS. Outcomes with as-needed ranibizumab after initial monthly therapy. Ophthalmology. 2015;122(12):2504–2513.e1. doi:10.1016/j.ophtha.2015.08.006
   PubMed Web of Science ®Google Scholar
• Bressler SB, Liu D, Glassman AR, et al. Change in diabetic retinopathy through 2 years. JAMA Ophthalmol. 2017;135(6):558. doi:10.1001/jamaophthalmol.2017.0821
   PubMed Web of Science ®Google Scholar
• Chang-Lin J-E, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Investig Opthalmology Vis Sci. 2011;52(1):80. doi:10.1167/iovs.10-5285
   PubMed Web of Science ®Google Scholar
• Zur D, Iglicki M, Loewenstein A. The role of steroids in the management of diabetic macular edema. Ophthalmic Res. 2019;62(4):231–236. doi:10.1159/000499540
   PubMed Web of Science ®Google Scholar
• Iglicki M, Zur D, Fung A, et al. TRActional DIabetic reTInal detachment surgery with co-adjuvant intravitreal dexamethasONe implant: the TRADITION study. Acta Diabetol. 2019;56(10):1141–1147. doi:10.1007/s00592-019-01357-y
   PubMed Web of Science ®Google Scholar
• Mello Filho P, Andrade G, Maia A, et al. Effectiveness and safety of intravitreal dexamethasone implant (Ozurdex) in patients with diabetic macular edema: a real-world experience. Ophthalmologica. 2019;241(1):9–16. doi:10.1159/000492132
   PubMed Web of Science ®Google Scholar
• Iglicki M, Zur D, Busch C, Okada M, Loewenstein A. Progression of diabetic retinopathy severity after treatment with dexamethasone implant: a 24-month cohort study the ‘DR-Pro-DEX study’. Acta Diabetol. 2018;55(6):541–547. doi:10.1007/s00592-018-1117-z
   PubMed Web of Science ®Google Scholar
• Iglicki M, Busch C, Zur D, et al. Dexamethasone implant for diabetic macular edema in naive compared with refractory eyes. Retina. 2019;39(1):44–51. doi:10.1097/IAE.0000000000002196
   PubMed Web of Science ®Google Scholar
• Zur D, Iglicki M, Sala‐Puigdollers A, et al. Disorganization of retinal inner layers as a biomarker in patients with diabetic macular oedema treated with dexamethasone implant. Acta Ophthalmol. 2020;98(2). doi:10.1111/aos.14230.
   Web of Science ®Google Scholar
• European Medicines Agency (EMA). Ozurdex. Assessment Report. 2014. ozurdex-epar-summary-public_en.pdf.
   Google Scholar
• Augustin AJ, Kuppermann BD, Lanzetta P, et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmol. 2015;15(1):150. doi:10.1186/s12886-015-0148-2
   PubMed Web of Science ®Google Scholar
• Boyer DS, Yoon YH, Belfort R, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904–1914. doi:10.1016/j.ophtha.2014.04.024
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Nguyen QD, Hafiz G, et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology. 2013;120(3):583–587. doi:10.1016/j.ophtha.2012.09.014
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125–2132. doi:10.1016/j.ophtha.2012.04.030
   PubMed Web of Science ®Google Scholar
• Gross JG, Glassman AR, Jampol LM, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy. JAMA. 2015;314(20):2137. doi:10.1001/jama.2015.15217
   PubMed Web of Science ®Google Scholar
• Singer MA, Miller DM, Gross JG, et al. Visual acuity outcomes in diabetic macular edema with fluocinolone acetonide 0.2 μg/day versus ranibizumab plus deferred laser (DRCR protocol I). Ophthalmic Surg Lasers Imaging Retina. 2018;49(9):698–706. doi:10.3928/23258160-20180831-08
   PubMed Web of Science ®Google Scholar
• Singer MA, Kermany DS, Waters J, Jansen ME, Tyler L. Diabetic macular edema: it is more than just VEGF. F1000Research. 2016;5:1019. doi:10.12688/f1000research.8265.1
   Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):626–635.e2. doi:10.1016/j.ophtha.2010.12.028
   PubMed Web of Science ®Google Scholar
• Hall J. Correspondence. Retina. 2017;37(3):e34–e37. doi:10.1097/IAE.0000000000001547
   Web of Science ®Google Scholar
• Singh P, Chedid A, Deuchler SK, et al. The efficacy and safety outcomes of the 0.19 mg fluocinolone acetonide implant after prior treatment with the 0.7 mg dexamethasone implant in patients with diabetic macular edema. Int Med Case Rep J. 2018;11:265.
   Web of Science ®Google Scholar
• Vaz-Pereira S, Castro-de-Sousa J, Martins D, et al. The outcomes of switching from short- to long-term intravitreal corticosteroid implant therapy in patients with diabetic macular edema. Ophthalmic Res. 2020;63(2):114–121. doi:10.1159/000503036
   Web of Science ®Google Scholar
• Coelho J, Malheiro L, Melo Beirão J, Meireles A, Pessoa B. Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes. Clin Ophthalmol. 2019;13:1751–1759. doi:10.2147/OPTH.S201611
   PubMed Web of Science ®Google Scholar
• Rehak M, Busch C, Unterlauft J-D, Jochmann C, Wiedemann P. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment. Acta Diabetol. 2020;57(4):469–478. doi:10.1007/s00592-019-01439-x
   PubMed Web of Science ®Google Scholar
• Elbarky AM. Rapid structural and functional improvements with the 0.19 mg fluocinolone acetonide intravitreal implant for patients with DME and low visual acuity: 6-month data from the UAE. Clin Ophthalmol. 2020;14:823–830. doi:10.2147/OPTH.S238740
   Web of Science ®Google Scholar
• Bailey C, Chakravarthy U, Lotery A, et al. Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom. Eye. 2017;31(12):1707–1715. doi:10.1038/eye.2017.125
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Taylor SR, Koch FH, et al. Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries. Br J Ophthalmol. 2018:1–6.
   Web of Science ®Google Scholar
• Augustin AJ, Atorf J, McGahan MC. The first European report of real-life clinical outcomes after 3 years of treatment with ILUVIEN® (fluocinolone acetonide) in patients with chronic diabetic macular edema (DME). Invest Ophthalmol Vis Sci. 2017;58(2):928. doi:10.1167/iovs.16-20610
   Web of Science ®Google Scholar